Sec Form 13D Filing - CBI USA Inc. filing for EXICURE INC PAR $0.0001 (XCUR) - 2023-01-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Schedule 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

EXICURE, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

30205M101

(CUSIP Number)

Kyungwon Oh

Chief Executive Officer

CBI USA, Inc.

3000 Western Avenue #400

Seattle, WA 98121

(425) 220-2542

With copy to:

John J. Harrington

Baker & Hostetler LLP

127 Public Square, Suite 2000

Cleveland, Ohio 44114-1214

Telephone: (216) 621-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

January 20, 2023

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §240.13d-1(e), §240.13d-1(f) or §240.13d-1(g), check the following box:  ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 30205M101

SCHEDULE 13D

This Amendment No. 4 (“Amendment No. 4”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on June 1, 2022 (the “Initial Schedule 13D” and together with Amendment No. 1 thereto filed with the SEC on October 31, 2022 (“Amendment No. 1”), Amendment No. 2 thereto filed with the SEC on December 5, 2022 (“Amendment No. 2”) and Amendment No. 3 thereto filed with the SEC on December 19, 2022 (Amendment No. 3”), the “Schedule 13D”) by CBI USA, Inc. (the “Reporting Person”) with respect to the Common Stock, par value $0.0001 per share, of Exicure, Inc. (“Exicure” or the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment No. 4 shall have the meanings set forth in the Schedule 13D. This Amendment No. 4 amends Items 3 and 5 to the extent set forth below.

Item 3. Source and Amount of Funds

Item 3 is amended and restated in its entirety as follows:

The Reporting Person previously disclosed its expectation to use its available working capital together with funds from CBI Co to fund the acquisition pursuant to the Securities Purchase Agreement. Although the Reporting Person and CBI Co have sufficient available funds to complete the acquisition, they now expect they may obtain outside funding for all or a portion of the purchase price. If outside funding is to be obtained, the Reporting Person will further amend this Schedule 13D to provide the disclosure required by this Item 3 promptly once determined.

Item 5. Interest in Securities of the Issuer

Item 5 is supplemented as follows:

The Reporting Person previously disclosed that the transactions contemplated by the Securities Purchase Agreement were expected to close no later than January 20, 2023. The Reporting Person now expects the transactions to close no later than February 10, 2023, subject to satisfaction or waiver of closing conditions.

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Date: January 20, 2023